Capital Royalty’s Strategic Advisory Committee (SAC) is comprised of world-class leaders with extensive experience in building global biopharmaceutical companies, managing large scale research and development initiatives, and developing national healthcare policies. Capital Royalty’s SAC was created to support the firm’s investment team in identifying emerging industry trends, broadening industry relationships around the globe, and evaluating new investment opportunities.
SIDNEY TAUREL - Senior Advisor and Chairman of the Strategic Advisory Committee
Sidney Taurel is Chairman Emeritus of Eli Lilly and Company. Mr. Taurel joined Eli Lilly and Company in 1971 and worked at the company for 37 years, 15 of which were spent on international assignments based in Sao Paulo, Vienna, Paris, and London.
DR. MARK MCCLELLAN, M.D., PH.D. - Member of the Strategic Advisory Committee
Dr. McClellan is Senior Fellow, Director of the Engelberg Center for Health Care Reform, and Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution. He is a former Administrator of the Centers for Medicare & Medicaid Services and former Commissioner of the Food and Drug Administration.
HENRI TERMEER - Member of the Strategic Advisory Committee
Henri A. Termeer was appointed President of Genzyme Corporation in 1983, two years after the company's founding. He became its Chief Executive Officer in 1985 and Chairman in 1988. Under his leadership, Genzyme has grown to one of the world's leading biotechnology companies.
DR. JOHN MENDELSOHN - Member of the Strategic Advisory Committee
Dr. John Mendelsohn is the Past-President of The University of Texas MD Anderson Cancer Center and Co-Director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.